0001832511-26-000022
SEC filingP3 Health Partners achieved net income of $3.0M in Q1 2026, driven by a 10% reduction in medical expense and a $13.5M related-party claims reduction, despite a 10% member decline.
P3 Health Partners Inc. reported a significant financial turnaround for the three months ended March 31, 2026, achieving net income of $3.0 million compared to a net loss of $44.2 million in the prior year period. This improvement was primarily driven by a substantial reduction in medical expenses and a favorable swing in income tax provision.
Total operating revenue increased 4% year-over-year to $386.4 million. The core capitated revenue stream grew 3% to $379.5 million, driven by an increase in the average per-member rate resulting from ongoing strategic contractual restructuring and improved burden of illness documentation. This rate increase was partially offset by a 10% decline in average at-risk members, which fell from 117,700 to 106,400, a result of previously disclosed intentional network and payer rationalization. Other revenue, a smaller component, increased 86% to $6.9 million.
Operating performance improved dramatically. Total operating expense decreased by 8% to $378.2 million. The primary driver was a 10% decrease in medical expense to $336.0 million, attributed to the lower member count, favorable reserve development, and a notable $13.5 million reduction of prior period medical claims expense from a related party. This led to a gross profit of $50.4 million, a stark contrast to the $1.2 million gross profit in Q1 2025. The gross margin expanded to 13.0% from 0.3%. Operating income was $8.2 million, compared to an operating loss of $38.1 million in the prior year.
Below the operating line, interest expense increased significantly to $16.8 million from $8.7 million, reflecting the cost of recent financing activities. However, a substantial income tax benefit of $11.0 million was recorded, compared to a $1.1 million provision in the prior year. This benefit was largely driven by the release of $6.4 million in uncertain tax positions and $2.4 million in associated interest and penalties. Consequently, net income attributable to the controlling interest was $1.2 million.
The company operates a single, integrated population health management model, and its results are not reported by distinct operating segments. The core dynamic is the management of its capitated at-risk membership. While the intentional rationalization of unprofitable contracts led to a 10% decline in average at-risk members to 106,400, the strategy successfully improved the quality of revenue. The remaining membership base generated a higher average PMPM rate, demonstrating the benefit of focusing on more profitable contracts and improving documentation of patient acuity.
The non-GAAP metric Medical Margin, which is capitated revenue less medical claims expense, highlights this dynamic, increasing to $73.7 million from $17.2 million. Platform support costs, which are expected to decrease as a percentage of revenue over time, were $20.7 million, or 5.4% of total operating revenue, a slight increase from 5.1% in the prior year, reflecting ongoing investment in the care model infrastructure.
Management's outlook is dominated by a going concern warning. The company stated that its existing cash resources of $25.5 million as of March 31, 2026, are not sufficient to support planned operations for at least the next year, raising substantial doubt about its ability to continue as a going concern. To address this, the company is actively exploring raising additional capital through debt and equity issuances. Subsequent to the quarter end, on April 27, 2026, the company entered into an agreement to issue up to $70.0 million of Series D Preferred Stock, with $30.0 million funded by April 30, 2026. The company expects to continue to incur net losses and negative cash flows from operations in accordance with its operating plan. Strategic priorities remain focused on managing medical costs, growing membership in existing and new markets, and achieving operating efficiencies to reach sustainable profitability.
As of March 31, 2026, P3 Health Partners Inc. reported unrestricted cash of $25.5 million, a slight increase from $25.0 million at year-end 2025. The Company's balance sheet is under severe stress, evidenced by a working capital deficit of $353.3 million and a total stockholders' deficit of $143.5 million. Total assets were $674.2 million, weighed down by $472.9 million in net intangible assets. Total liabilities stood at $807.3 million. Critically, Note 2 explicitly states that "substantial doubt exists about the Company's ability to continue as a going concern for one year after the date the financial statements are issued," citing historical losses, the working capital deficit, and uncertainty around raising additional capital.
The Notes do not contain a standard purchase commitments table. However, significant financing commitments are detailed. The VGS 5 Promissory Note, amended in February 2026, had its third tranche availability extended to June 30, 2026. During Q1 2026, the Company drew the final $27.0 million of the $70.0 million facility. Gross long-term debt increased to $379.3 million, with net debt at $311.0 million after unamortized discounts and issuance costs. The current portion of long-term debt is $51.4 million. A subsequent event on April 27, 2026, fundamentally altered the capital structure: $252.5 million of VGS 1-5 promissory notes were exchanged for non-convertible, non-voting preferred stock, and a new $70.0 million preferred stock purchase agreement was executed, with $30.0 million funded immediately.
Capital allocation in Q1 2026 was dominated by debt financing. The Company received $27.0 million in proceeds from long-term debt, net of original issue discount, and $1.0 million from short-term debt, while repaying $0.2 million. No dividends or share buybacks were reported. The Company issued equity-classified warrants to purchase 1.3 million shares of Class A common stock with a fair value of $3.0 million, recorded in additional paid-in capital. The subsequent debt-for-preferred-stock exchange and new preferred stock issuance represent a major recapitalization effort to address the going concern risk.
The Company operates under a single reportable segment, as disclosed in Note 10. Total operating revenue for the segment was $386.4 million for Q1 2026, a 3.5% increase from $373.2 million in Q1 2025. Capitated revenue dominated at $379.5 million (98.2% of total revenue). The segment reported an operating income of $8.2 million, a significant turnaround from a $38.1 million loss in the prior year period, driven by a reduction in medical claims expense. Customer concentration is high, with four health plan customers accounting for 63% of total revenue during the quarter.
For the three months ended March 31, 2026, P3 Health Partners reported a net income of $3.0 million, a significant turnaround from a net loss of $44.2 million in the prior year. Despite this positive net income, the company's operating cash flow remained negative at -$27.5 million, though this represents an 18% improvement from the -$33.5 million used in Q1 2025. The primary driver of the negative operating cash flow was a substantial $32.4 million increase in health plan receivables, coupled with a $21.6 million decrease in health plan settlements payable. These working capital swings, which consumed over $54 million in cash, were partially offset by non-cash adjustments, including $21.1 million in depreciation and amortization and $10.8 million in paid-in-kind interest expense.
The company did not disclose any capital expenditures (capex) in the provided cash flow statement. Investing activities were minimal, with a net cash outflow of just $43,000. No share repurchases or dividends were paid during the period. The company remains reliant on external financing to fund operations, as evidenced by $27.8 million in net cash provided by financing activities, primarily from $27.0 million in long-term debt proceeds. The company's cash position remains tight at $26.1 million, and the accompanying notes highlight substantial doubt about its ability to continue as a going concern.